All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Polyneuron Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy

Contact the Supplier

Lead Product(s): PN-1007

Therapeutic Area: Immunology

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

Regulatory authorities in France, the Netherlands and the UK have approved the clinical trial application for a phase I/IIa study of PN?1007 for the treatment of anti-MAG neuropathy.